Calidi closes $6M public offering; existing warrants amended to $0.50 exercise price

Calidi Biotherapeutics, Inc.

Gross proceeds of $6.03M from 12,094,631 units sold (including full over-allotment exercise).
Each unit priced at $0.50 and consists of common stock (or pre-funded warrant) plus Series J (5 yr), K (1 yr) and L (6 mo) warrants.
Existing warrants for ~2.97M shares (Series G/H/I) amended to exercise price of $0.50 per share.
Company had 10,545,725 common shares outstanding as of March 11, 2026, post-offering.
Proceeds to be used for working capital and general corporate purposes.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.7

Calidi Biotherapeutics, Inc. entered into Warrant Agency Agreement with Equiniti Trust Company, LLC (effective 2026-03-06).

Action: entry
Counterparty: Equiniti Trust Company, LLC
Effective: 2026-03-06

Exact text from the filing

On March 6, 2026, the Company also entered into a warrant agency agreement (the “Warrant Agency Agreement”) with Equiniti Trust Company, LLC, as warrant agent (the “Warrant Agent”).

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Calidi Biotherapeutics, Inc. entered into Underwriting Agreement with Ladenburg Thalmann & Co. Inc. valued at approximately $6.03 million (effective 2026-03-06).

Action: entry
Agreement: underwriting
Counterparty: Ladenburg Thalmann & Co. Inc.
Value: approximately $6.03 million
Effective: 2026-03-06

Exact text from the filing

On March 6, 2026, Calidi Biotherapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Ladenburg Thalmann & Co. Inc., as sole underwriter (“Underwriter”), in connection with the issuance and sale (the “Offering”) of: (i) 2,278,731 common stock units (“Common Stock Units”), which includes 1,575,000 Common Stock Units purchased pursuant to the exercise, in full, of the Over-Allotment Option and (ii) 9,815,900 pre-funded warrant units (“Pre-Funded Units”), resulting in gross proceeds of approximately $6.03 million, before deducting underwriting discounts and commissions and other estimated offering expenses.

View on SEC.gov

317 material agreements filed in the last 30 days. Browse all material agreements →

Calidi Biotherapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-26-009701

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.